A multicenter, randomized controlled trial of tamibarotene (OMS0728) in relapsed or refractory acute promyelocytic leukemia (APL).
Phase of Trial: Phase III
Latest Information Update: 03 May 2016
At a glance
- Drugs Tamibarotene (Primary) ; Arsenic trioxide
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 19 Apr 2016 New trial record